Multiple Myeloma Clinical Trial
— RENVELOfficial title:
A National, Multicentric, Open-label Study of Induction Treatment With VELCADE and Dexamethasone for Previously Untreated Patients With Multiple Myeloma and Renal Failure
Verified date | September 2015 |
Source | PETHEMA Foundation |
Contact | n/a |
Is FDA regulated | No |
Health authority | Spain: Ministry of Health |
Study type | Interventional |
Primary outcome measure:
- Analyze the efficacy (in order to evaluate the response) of Bortezomib/Dexamethasone
treatment
Secondary outcome measures:
- Study the speed of response and the response rate (M component in serum and urine
protein) after each bortezomib/dexamethasone cycle
- Compare the efficacy of the bortezomib/dexamethasone therapy against the therapy
without bortezomib
- Reversibility of renal failure
- Predictive value in the light chain determination for response and reversibility of
renal failure
- Early morbidity (< 2 months)
- Progression-free survival
- Overall survival
The safety outcome consists in:
- Determining the safety and tolerance of VELCADE/Dexamethasone, according to the
toxicity criteria of clinical and laboratory events
Status | Completed |
Enrollment | 60 |
Est. completion date | December 2013 |
Est. primary completion date | September 2012 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - The patient must, according with investigator criteria, be able to comply with all the protocol requirements - The patient or legal representative must sign voluntarily the informed consent before the performance of any study related procedure, not part of usual medical care, with the knowledge that can leave the study the moment he/she wants, without prejudice to later medical care - 18 years and older - Patients with newly diagnosed symptomatic multiple myeloma43 which hasn`t been treated previously with any chemotherapy used for this disease (see Annex 8) - Patient with a measurable or evaluable disease, defined as follows: - For secretor multiple myeloma, measurable disease is defined as any quantifiable serum monoclonal protein value of IgG>10g/l or IgA > 5 g/l and, where applicable, urine light-chain excretion of = 200 mg/24 hours - For oligo or non-secretor multiple myeloma, measurable disease is defined by the presence of soft tissue plasmocytomas (not bone) determined by clinical examination or applicable radiographs (i.e. MRI, CT-Scan). In patients with low secretor multiple myeloma, the serum and/or urine M-protein measurements are very low and difficult to follow for response assessment. In patients with non-secretor multiple myeloma, there is no M-protein in serum or urine by immunofixation - ECOG performance status = 2 (see Appendix 5) - Patient has a life-expectancy >3 months - Glomerular filtration calculated with MDRD <50 ml/min - Patient has the following laboratory values during the 14 days before first dose: - Platelet count = 50x109/l - Absolute neutrophil count (ANC) = 0.75 x 10 9/ L - Corrected serum calcium (see Appendix 15) = 14mg/dl - Aspartate transaminase (AST): = 2,5 x upper limit of normal - Alanine Aminotransferase (ALT): = 2,5 x upper limit of normal - Total bilirubin: = 1,5 x upper limit of normal Exclusion Criteria: - Glomerular filtration calculated with MDRD = 50ml/min - Asymptomatic MM with renal failure from unrelated causes - Prior Velcade therapy - Patients previously received treatment to Multiple Myeloma - Patient had major surgery within 4 weeks previous inclusion - Patient with platelet count = 50 x 109/l within 14 days before enrolment - Patient with absolute neutrophil count = 0,75x109/l within 14 days before enrolment - Patients with Grade 2 peripheral neuropathy within 14 days before enrolment - Patient has hypersensitivity to bortezomib, boron or mannitol - Patient has received other investigational drugs within 14 days before enrolment - Patient is known to be seropositive for the human immunodeficiency virus (HIV) - Patient had a myocardial infarction within 6 months before of enrolment or has Class III or IV heart failure (New York Heart Association <NYHA>), uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiography evidence of acute ischemia or active conduction system abnormalities, or other heart condition which, according with the specialist, can result in heart failure - Patient is enrolled in another clinical research study and/or is receiving an investigational agent for any reason - Patients with diffuse pulmonary disease and/or pericardial disease - Pregnancy or breast-feed women and women of childbearing age that don't accept to use anticonceptive methods since beginning during all the study until 30 days after last cycle treatment. Fertile male patients must use effective form of contraception since enrolment, during and until 30 days after last cycle study treatment - Patient with a previous clinical history of another malign illness except for squamous cell carcinoma or skin cancer or cervical or breast cancer) except the patient could be free of symptoms during = 5 years - Uncontrolled arterial hypertension or diabetes mellitus or other serious medical condition which places the subject at unacceptable risk or other psychiatric illness that would prevent the subject from understanding the informed consent form |
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Spain | Hospital Germans Trias i Pujol | Badalona | Barcelona |
Spain | Hospital Clinic | Barcelona | |
Spain | Hospital de Sant Pau | Barcelona | |
Spain | Hospital 12 de Octubre | Madrid | |
Spain | Hospital Clínico San Carlos | Madrid | |
Spain | Hospital Ramón y Cajal | Madrid | |
Spain | Hospital Universitario | Salamanca | |
Spain | Hospital General | Segovia | |
Spain | Hospital Universitario de Canarias | Tenerife | |
Spain | Hospital La Fe | Valencia | |
Spain | Hospital Lozano Blesa | Zaragoza |
Lead Sponsor | Collaborator |
---|---|
PETHEMA Foundation |
Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Efficacy | Analyze the efficacy (in order to evaluate the response) of Bortezomib/Dexamethasone treatment | 2 years | No |
Secondary | Progression-free survival | 2 years | No | |
Secondary | Overall survival | 4 years | No | |
Secondary | Safety | Determining the safety and tolerance of VELCADE/Dexamethasone, according to the toxicity criteria of clinical and laboratory events | 1 year | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05027594 -
Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
Completed |
NCT02412878 -
Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma
|
Phase 3 | |
Completed |
NCT01947140 -
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05971056 -
Providing Cancer Care Closer to Home for Patients With Multiple Myeloma
|
N/A | |
Recruiting |
NCT05243797 -
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
|
Phase 3 | |
Active, not recruiting |
NCT04555551 -
MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma
|
Phase 1 | |
Recruiting |
NCT05618041 -
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
|
N/A | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
Completed |
NCT02916979 -
Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG
|
Phase 1 | |
Recruiting |
NCT03570983 -
A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion
|
Phase 2 | |
Terminated |
NCT03399448 -
NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)
|
Phase 1 | |
Completed |
NCT03665155 -
First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody
|
Phase 1/Phase 2 | |
Completed |
NCT02812706 -
Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05024045 -
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
|
Phase 1 | |
Active, not recruiting |
NCT03989414 -
A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03792763 -
Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients
|
Phase 2 | |
Withdrawn |
NCT03608501 -
A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation
|
Phase 2 | |
Recruiting |
NCT04537442 -
Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
Completed |
NCT02546167 -
CART-BCMA Cells for Multiple Myeloma
|
Phase 1 |